UY31282A1 - Intermediarios y métodos de preparacion de ésteres de derivados sustituidos del acido carboxilico 4-(2-oxo-1,2,4,5-tetrahidro-1,3-benzoldiazepina-3yl)-piperidina-1, sales farmacéuticamente aceptadas, isomeros, - Google Patents

Intermediarios y métodos de preparacion de ésteres de derivados sustituidos del acido carboxilico 4-(2-oxo-1,2,4,5-tetrahidro-1,3-benzoldiazepina-3yl)-piperidina-1, sales farmacéuticamente aceptadas, isomeros,

Info

Publication number
UY31282A1
UY31282A1 UY31282A UY31282A UY31282A1 UY 31282 A1 UY31282 A1 UY 31282A1 UY 31282 A UY31282 A UY 31282A UY 31282 A UY31282 A UY 31282A UY 31282 A1 UY31282 A1 UY 31282A1
Authority
UY
Uruguay
Prior art keywords
benzoldiazepina
piperidina
tetrahidro
esteres
intermediaries
Prior art date
Application number
UY31282A
Other languages
English (en)
Inventor
Bianca Werner
Svenja Renner
Carsten Reichel
Thomas Fachinger
Emanuel Stehle
Joern Merten
Thomas Krueger
Michael Konrad
Juergen Schnaubelt
Rolf Schmid
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of UY31282A1 publication Critical patent/UY31282A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/96—Esters of carbonic or haloformic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrane Compounds (AREA)

Abstract

Es objeto de la presente invencion un procedimiento para preparar compuestos de la formula general I en la que R1 y R2 se definen como se menciona en la descipcion, sus sales y solvatos de tolerancia farmacéutica, que se pueden obtener a partir de compuestos de la formula general II en la que R1 se define como se menciona en la descripcion.
UY31282A 2007-08-13 2008-08-11 Intermediarios y métodos de preparacion de ésteres de derivados sustituidos del acido carboxilico 4-(2-oxo-1,2,4,5-tetrahidro-1,3-benzoldiazepina-3yl)-piperidina-1, sales farmacéuticamente aceptadas, isomeros, UY31282A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102007038251A DE102007038251A1 (de) 2007-08-13 2007-08-13 Neues Herstellverfahren

Publications (1)

Publication Number Publication Date
UY31282A1 true UY31282A1 (es) 2009-03-31

Family

ID=39874112

Family Applications (1)

Application Number Title Priority Date Filing Date
UY31282A UY31282A1 (es) 2007-08-13 2008-08-11 Intermediarios y métodos de preparacion de ésteres de derivados sustituidos del acido carboxilico 4-(2-oxo-1,2,4,5-tetrahidro-1,3-benzoldiazepina-3yl)-piperidina-1, sales farmacéuticamente aceptadas, isomeros,

Country Status (16)

Country Link
US (1) US8288531B2 (es)
EP (1) EP2188275A2 (es)
JP (1) JP2010535838A (es)
KR (1) KR20100052531A (es)
CN (1) CN101821258A (es)
AR (1) AR068807A1 (es)
AU (1) AU2008288430A1 (es)
BR (1) BRPI0815419A2 (es)
CA (1) CA2696257A1 (es)
CL (1) CL2008002377A1 (es)
DE (1) DE102007038251A1 (es)
MX (1) MX2010001512A (es)
PE (1) PE20090515A1 (es)
TW (1) TW200918518A (es)
UY (1) UY31282A1 (es)
WO (1) WO2009021943A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007038250A1 (de) * 2007-08-13 2009-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neues Herstellverfahren
CN103601722B (zh) * 2013-09-13 2016-03-02 南京华威医药科技开发有限公司 新型抗肿瘤化合物
CN105777615A (zh) * 2016-04-07 2016-07-20 戊言医药科技（上海）有限公司 4-吗啉代哌啶的制备方法
JP6927548B2 (ja) 2016-05-07 2021-09-01 シャンハイ フォチョン ファーマシューティカル カンパニー リミテッド ある種のタンパク質キナーゼ阻害剤
ES2906356T3 (es) * 2016-06-09 2022-04-18 Yuki Gosei Yakuhin Kogyo Kk Método para preparar 4-(piperidin-4-il)morfolina

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904421D0 (sv) * 1999-12-03 1999-12-03 Astra Ab New compounds
ATE483699T1 (de) * 2002-08-30 2010-10-15 Hoffmann La Roche Neue 2-arylthiazolverbindungen als ppar-alpha und gamma agonisten
EP1619187A1 (de) 2004-07-23 2006-01-25 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Herstellung von 3-(4-Piperidinyl)- 2,3,4,5-tetrahydro-1,3-benzodiazepin-2(1H)-on
EP1770091A1 (de) * 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
EP1770086A1 (de) * 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102005061472A1 (de) * 2005-12-22 2007-07-05 Saltigo Gmbh Verfahren zur Herstellung von enantiomerenangereicherten 2-Alkoxy-3-phenylpropionsäuren

Also Published As

Publication number Publication date
WO2009021943A3 (de) 2009-04-30
AR068807A1 (es) 2009-12-09
WO2009021943A2 (de) 2009-02-19
US20110087021A1 (en) 2011-04-14
US8288531B2 (en) 2012-10-16
CN101821258A (zh) 2010-09-01
BRPI0815419A2 (pt) 2015-02-03
AU2008288430A1 (en) 2009-02-19
KR20100052531A (ko) 2010-05-19
PE20090515A1 (es) 2009-05-28
CL2008002377A1 (es) 2009-10-23
CA2696257A1 (en) 2009-02-19
EP2188275A2 (de) 2010-05-26
DE102007038251A1 (de) 2009-02-19
MX2010001512A (es) 2010-03-10
JP2010535838A (ja) 2010-11-25
TW200918518A (en) 2009-05-01

Similar Documents

Publication Publication Date Title
BR112012032244A2 (pt) processo para preparar derivados de antranilamida com tetrazole-substituído e polimorfos cristalinos novos e derivados destes
ECSP13012611A (es) Derivados de pirazol-aminopirimidina como moduladores de la lrrk2
DOP2014000203A (es) Compuestos de heterociclilo
ECSP099755A (es) Derivados de pirrolopiridina y su uso como inhibidores de bace
UY30408A1 (es) Derivados sustituidos del acetato de 8-(4-metoxifenil)-2,3,4,8-tetrahidroimidazo-[1,5-a]-pirimidin-6-amina, composiciones farmacéuticas y aplicaciones
ECSP14006132A (es) Derivados de ácido benzotiazol-6-il acético y su uso para tratar una infección por vih
ECSP10010582A (es) Derivados de aminodihidrotiazina como inhibidores de bace para el tratamiento de la enfermedad de alzheimer
CR20140399A (es) Pirrolidina-2-carboxamidas sustituidas
MX2013001614A (es) Compuestos heterociclico.
BR112013023517A2 (pt) "inibidores de produção de leucotrieno, seus usos, e composição farmacêutica"
MX348606B (es) Derivados de aminopirimidina como moduladores de proteina cinasa 2 de repeticion rica en leucina (lrrk2).
DOP2016000276A (es) 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS
BR112012029647A2 (pt) novos derivados de pirimidinas
CO6680645A2 (es) Inhibidores de oxadiazol de la producción de leucotrieno
ECSP11010992A (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), producción y uso de los mismos como productos medicinales
BR112014000471A2 (pt) processo para preparo de derivados de diamida de ácido antranílico substituídos com tetrazol por meio da reação de ácidos pirazóis com ésteres antranílicos
UY34893A (es) Derivados de azaindol
ECSP088700A (es) Acidos 4-fenil-tiazol-5-carboxilicos y amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1
EA201792071A2 (ru) Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения
UY31282A1 (es) Intermediarios y métodos de preparacion de ésteres de derivados sustituidos del acido carboxilico 4-(2-oxo-1,2,4,5-tetrahidro-1,3-benzoldiazepina-3yl)-piperidina-1, sales farmacéuticamente aceptadas, isomeros,
CL2011000296A1 (es) Proceso de preparación del ester metílico del ácido 4-oxo-octahidro-indol-1-carboxílico y compuestos intermediarios utilizados.
CO2017003305A2 (es) Derivados de la amida del ácido 2-[piridin-3-il]-2,3-dihidro-benzo[1,4]dioxin-5-carboxílico o del 2-[piridin-3-il]-2,3-dihidro-benzo[1,4]dioxin-5-carbonitrilo como inhibidores de aldosterona sintasa
UY30851A1 (es) Proceso para la sintesis de derivados de acido 3-amino-tetrahidrofuran-3-carboxilico y uso de los mismos como medicamentos
ECSP13012548A (es) Inhibidores de oxadiazol de la producción de leucotrienos.
BRPI0808570B8 (pt) processo para a preparação de inibidores de glyt-1

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20171011